Iskra will help Cleveland Diagnostics scale up commercial adoption of its IsoPSA blood-based test that analyzes the structure of protein biomarkers for prostate cancer signals.
Iskra will help Cleveland Diagnostics scale up commercial adoption of its IsoPSA blood-based test that analyzes the structure of protein biomarkers for prostate cancer signals.